Literature DB >> 16895476

Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata.

Pamela Hamill1, Derek Hudson, Richard Y Kao, Polly Chow, Meera Raj, Hongyan Xu, Martin J Richer, François Jean.   

Abstract

SARS-coronavirus (SARS-CoV) encodes a main protease, 3CLpro, which plays an essential role in the viral life cycle and is currently the prime target for discovering new anti-coronavirus agents. In this article, we report our success in developing a novel red-shifted (RS) fluorescence-based assay for 3CLpro and its application for identifying small-molecule anti-SARS agents from marine organisms. We have synthesised and characterised the first generation of a red-shifted internally quenched fluorogenic substrate (RS-IQFS) for 3CLpro based on resonance energy transfer between the donor and acceptor pair CAL Fluor Red 610 and Black Hole Quencher-1 (Km and kcat values of 14 microM and 0.65 min-1). The RS-IQFS primary sequence was selected based on the results of our screening analysis of 3CLpro performed using a series of blue-shifted (BS)-IQFSs corresponding to the 3CLpro-mediated cleavage junctions of the SARS-CoV polyproteins. In contrast to BS-IQFSs, the RS-IQFS was not susceptible to fluorescence interference from coloured samples and allowed for successful screening of marine natural products and identification of a coumarin derivative, esculetin-4-carboxylic acid ethyl ester, a novel 3CLpro inhibitor (IC50=46 microM) and anti-SARS agent (EC50=112 microM; median toxic concentration>800 microM) from the tropical marine sponge Axinella corrugata.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16895476     DOI: 10.1515/BC.2006.131

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  6 in total

1.  Perspectives on SARS-CoV-2 Main Protease Inhibitors.

Authors:  Kaifu Gao; Rui Wang; Jiahui Chen; Jetze J Tepe; Faqing Huang; Guo-Wei Wei
Journal:  J Med Chem       Date:  2021-11-19       Impact factor: 8.039

Review 2.  Nature as a treasure trove of potential anti-SARS-CoV drug leads: a structural/mechanistic rationale.

Authors:  Ahmed M Sayed; Amira R Khattab; Asmaa M AboulMagd; Hossam M Hassan; Mostafa E Rateb; Hala Zaid; Usama Ramadan Abdelmohsen
Journal:  RSC Adv       Date:  2020-05-27       Impact factor: 4.036

3.  Human subtilase SKI-1/S1P is a master regulator of the HCV Lifecycle and a potential host cell target for developing indirect-acting antiviral agents.

Authors:  Andrea D Olmstead; Wolfgang Knecht; Ina Lazarov; Surjit B Dixit; François Jean
Journal:  PLoS Pathog       Date:  2012-01-05       Impact factor: 6.823

Review 4.  Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection.

Authors:  Seyed Abdulmajid Ayatollahi; Javad Sharifi-Rad; Patrick Valere Tsouh Fokou; Gail B Mahady; Hafiz Ansar Rasul Suleria; Shivani Krishna Kapuganti; Kundlik Gadhave; Rajanish Giri; Neha Garg; Rohit Sharma; Daniel Ribeiro; Célia F Rodrigues; Željko Reiner; Yasaman Taheri; Natália Cruz-Martins
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

5.  Biochemical screening for SARS-CoV-2 main protease inhibitors.

Authors:  Camila Coelho; Gloria Gallo; Claudia B Campos; Leon Hardy; Martin Würtele
Journal:  PLoS One       Date:  2020-10-06       Impact factor: 3.240

6.  Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.

Authors:  Hazem Mslati; Francesco Gentile; Carl Perez; Artem Cherkasov
Journal:  J Chem Inf Model       Date:  2021-07-27       Impact factor: 4.956

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.